Related Experiment Video

Updated: Jun 29, 2025

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.7K

Therapeutic Options Targeting the Ataxia-Telangiectasia Mutated (ATM)-mediated DNA Damage Response, Macropinocytosis,

Cai-Chieh Tseng1, Min-Hsi Ku1, Yun-Chieh Wu1

  • 1Department of Life Science, College of Science and Engineering, National Dong Hwa University, Hualien, Taiwan, R.O.C.

Anticancer Research
|March 27, 2024
PubMed

Insights

Targeting the ATM protein in ovarian cancer offers new treatment strategies. This approach can address DNA repair deficiencies, impact cellular processes, and improve immunotherapy effectiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Ataxia-telangiectasia mutated (ATM) is a key protein kinase involved in DNA damage response.
  • ATM's role in DNA repair is established, but its noncanonical functions in ovarian cancer are less understood.
  • ATM is a potential therapeutic target for ovarian cancer.

Purpose of the Study:

  • To review the current evidence on targeting ATM in ovarian cancer.
  • To explore ATM's roles beyond DNA repair, including metabolism and immunity.
  • To provide a perspective on ATM-targeted therapies for ovarian cancer.

Main Methods:

  • Literature review of studies on ATM in ovarian cancer.
  • Analysis of ATM's involvement in homologous recombination repair (HRR).
  • Examination of ATM's influence on macropinocytosis and adaptive immunity.

Main Results:

  • ATM plays a role in HRR-deficient ovarian cancer genotypes.
  • ATM influences cellular metabolism, specifically macropinocytosis.
  • Targeting ATM may enhance the efficacy of immune checkpoint blockade (ICB) therapy.

Conclusions:

  • Targeting ATM presents a multifaceted strategy for ovarian cancer treatment.
  • ATM-targeted therapies can address HRR deficiency and modulate the tumor microenvironment.
  • ATM offers potential for tailored treatment approaches in ovarian cancer.
Keywords:
ATMDNA damage responseadaptive immunitymacropinocytosisovarian cancerreview

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
523
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K